Ignite Creation Date:
2024-05-06 @ 7:40 PM
Last Modification Date:
2024-10-26 @ 3:11 PM
Study NCT ID:
NCT06093698
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-10-23
First Post:
2023-10-10
Brief Title:
An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases
Sponsor:
ITabMed Co Ltd
Organization:
ITabMed Co Ltd
Study Overview
Official Title:
An Exploratory Study of A-337 in the Management of Malignant Solid Dose
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
A-337
Brief Summary:
Title An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases
Detailed Description:
Protocol Number IM-2021A Study Stage Phase I Study Number 2-3 sites Subject Number up to 94 patients with recurrent or metastatic solid tumors for whom there are no available effective standard treatments or for whom standard treatments have proven ineffective or intolerable
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None